AVTX - Avalo Therapeutics Stock Price, Chart, News and Analysis
AVTX news
Avalo Therapeutics, Inc. Common Stock (AVTX): What does the company do?
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Unlock full access
Every scanner, the BH Indicator, insider and options flow, sector and industry rankings, the themes, the trading journal and the daily briefings from the Senior Analyst.
See plans →Breakouts Happen publishes market analysis and screening tools. Every idea, opinion and forecast on this site — stated or implied — is provided for informational purposes only and is not a recommendation to invest, trade or speculate in any market. Any position taken in light of the material published here is taken at your own risk, financial or otherwise. Breakouts Happen is not a registered investment advisor, and nothing on this site is an offer or solicitation to buy or sell any security.
Market data is delayed and provided for reference only. Past performance does not indicate future results.